Lilly Shows Diabetes Dominance, But Will It Last?
Lilly's first quarter benefited from rising sales for most of its diabetes products, which has become one of the most difficult therapeutic areas to do business in due to competitive and reimbursement pressures.
You may also be interested in...
Lilly will save $500m annually starting in 2018 after $1.2bn in layoff-related costs to reinvest in new products. Also, Cytori halves its headcount; VC OrbiMed closed a $551m Asia fund; and Insmed capitalizes on positive data.
Part two of Scrip's preview of first quarter earnings: product launches, management priorities, pricing strategies and biosimilar competition are key themes at the half-year mark.
Cardiovascular outcomes trials headlined the recent ADA meeting. Scrip spoke with executives from Novo, Boehringer, AstraZeneca and Merck at the conference about the value of CV data and real world evidence in an era when managing diabetes is about much more than lowering blood glucose.